To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose (MTD), safety, and
tolerability of oral CEP-37440 administered daily to patients with advanced or metastatic
solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.